Last reviewed · How we verify
gatifloxacin ophthalmic solution 0.3%
Gatifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing bacterial DNA replication and transcription.
Gatifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing bacterial DNA replication and transcription. Used for Bacterial conjunctivitis, Bacterial corneal ulcers, Other bacterial ocular infections.
At a glance
| Generic name | gatifloxacin ophthalmic solution 0.3% |
|---|---|
| Also known as | ZYMAR® |
| Sponsor | Allergan |
| Drug class | Fluoroquinolone antibiotic |
| Target | DNA gyrase; Topoisomerase IV |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
As a fourth-generation fluoroquinolone, gatifloxacin works by binding to and inhibiting DNA gyrase (in gram-negative bacteria) and topoisomerase IV (in gram-positive bacteria), enzymes essential for bacterial DNA replication and repair. This dual mechanism results in rapid bactericidal activity against a broad spectrum of gram-positive and gram-negative ocular pathogens. When formulated as an ophthalmic solution, it achieves high local concentrations in ocular tissues to treat bacterial infections of the eye.
Approved indications
- Bacterial conjunctivitis
- Bacterial corneal ulcers
- Other bacterial ocular infections
Common side effects
- Conjunctival irritation
- Eye discomfort
- Taste perversion
- Photophobia
Key clinical trials
- Efficacy of the Ophthalmic Pazufloxacin 0.6% for Bacterial Conjunctivitis, Compared to Gatifloxacin 0.3%. (PHASE3)
- Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin) (PHASE2)
- Non-Inferiority of Gatifloxacin/Prednisolone Association vs Isolated Administration in Prevention of Ocular Infection/Inflammation (PHASE3)
- Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis (PHASE3)
- A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms (PHASE4)
- Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects (PHASE1)
- Effect of Moxifloxacin Versus Gatifloxacin on Corneal Epithelium Following Pterygium Excision (NA)
- Ocular Availability in Human Tears After Topical Administration of 1.5% Levofloxacin Compared to Active Comparators (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- gatifloxacin ophthalmic solution 0.3% CI brief — competitive landscape report
- gatifloxacin ophthalmic solution 0.3% updates RSS · CI watch RSS
- Allergan portfolio CI